Phosphoproteomics of Patient-Derived Xenografts Identifies Targets and Markers Associated with Sensitivity and Resistance to EGFR Blockade in Colorectal Cancer

Mass spectrometry–based proteomics and phosphoproteomics were performed on 30 genomically and pharmacologically characterized metastatic colorectal cancer patient–derived xenografts to investigate the molecular basis of response to epidermal growth factor receptor (EGFR) blockade and identify alternative drug targets to overcome resistance.